Effect of BioBran on head and neck cancer

Radiology Journal volume 12, February 2020
Dorothy Faye S. Tan et al.

Radiation/chemoradiotherapy is associated with decreased white blood cell counts, an increased risk of infection, and reduced quality of life. In this study, the authors conducted a double-blind, randomized, controlled trial to determine whether BioBran reduces the side effects of chemoradiotherapy.
Sixty-five head and neck cancer patients undergoing radiation or chemoradiotherapy received either BioBran or a placebo and were evaluated for anemia, leukopenia, and other side effects, as well as for improvements in quality of life. BioBran and placebo were taken daily at 3 g/day starting two weeks before treatment, and continuing throughout, and lasting two months afterward.
The BioBran group showed significantly higher levels of hemoglobin and hematocrit, and red blood cell count and platelet count (Tables 1 and 2) and less weight loss two months after chemoradiotherapy. QOL scores were also improved in the BioBran group (Tables 3 and 4). These results indicate that BioBran alleviates the side effects of chemoradiotherapy.

This page contains data that has been partially modified from the original tables in the article for optimal presentation on the website.